Home Celyad Treats First Patient of Second Cohort in NKG2D Car T-Cell Phase I Trial
 

Keywords :   


Celyad Treats First Patient of Second Cohort in NKG2D Car T-Cell Phase I Trial

2015-12-01 07:59:13| Semiconductors - Topix.net

Celyad , a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating the Company's NKG2D CAR T-Cell therapy in acute myeloid leukaemia and multiple myeloma indications. Dr. Christian Homsy, CEO of Celyad, said : " The treatment of the first patient enrolled in the second cohort of our first-in-man Phase I trial evaluating NKG2D CAR T-Cells demonstrates continued progress in developing our lead immune-oncology program.

Tags: car trial phase patient

Category:Electronics and Electrical

Latest from this category

All news

»
23.11PlayStationVitaPCH-2000
23.11GB
23.11 Malbon
23.11PING PEARL GATES
23.11WATCH
23.11L
23.11Tetsuya_SP2 DMC
23.116
More »